Skip to content

Evaluation of the Efficiency of Autologous Platelet Gel (Platelet Rich Fibrin) Obtained From Own Patients' Blood Versus Vaselitulle in Dupuytren's Disease Postoperative Wound Healing

Evaluation of the Efficiency of Autologous Platelet Gel (Platelet Rich Fibrin) Obtained From Own Patients' Blood Versus Vaselitulle in Dupuytren's Disease Postoperative Wound Healing

Status
Completed
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00931567
Enrollment
80
Registered
2009-07-02
Start date
2007-08-31
Completion date
2010-02-28
Last updated
2012-03-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dupuytren's Contracture

Brief summary

This study is a clinical, multicentric, randomised open trial. The objective is to evaluate the efficiency, in terms of wound healing speed, of peroperative application of autologous platelets gel versus standardized wound dressing. The wound Healing model used in this study is the open palm surgical treatment of Dupuytren's disease. Dupuytren's disease is a fibroproliferative disease of the palmar and digital fascia of the hand that may lead to a fixed flexion contracture of the fingers. The main indication for surgery is the loss of finger extension. In some cases of palmar Dupuytren's disease the surgical removal of diseased tissues may lead to a cutaneous loss of substance ( open palm technique ). This loss of substance is treated using vaseline dressing and the wound healing is obtained in 4 weeks. Autologous platelets gel (Platelet Rich Fibrin) is obtained from the patient's own blood. Some recent studies have shown that it speeds up the wound healing and enhances the quality of the scar. PRF belongs to a new generation of autologous platelet gel that are easily obtained after centrifugation of patient's own blood. The Platelet Rich Fibrin (PRF) contains many wound healing factors : Three pro inflammatory cytokines ( IL1,IL6, TNF-alpha) , one anti-inflammatory cytokine (IL4) and a growth factor (VEGF). The study will be running on 60 days, starting from the operation day. The wound healing evaluation will be achieved at day1, day2, day7, day14, day 21 day 28 and day 60. The inclusion criteria are : age over 18, Dupuytren's disease with an indication of surgical treatment using the open palm technique, patients having signed the agreement form. 80 patients will be included in the study and divided into 2 groups . The first group of patients will receive PRF and the other group will receive vaseline dressings. The speed and the quality of wound healing will be compared.We will also compare the number of patients with a complete wound healing at day 21 . Moreover,we will evaluate the pain during the dressings' change and the bleeding of the palmar wound. For the wound healing speed , a difference of 7 days between the two groups will be considered as statistically significant. Statistical analysis will be achieved using Chi2 test and Logrank test.

Detailed description

Main evaluation criteria : Time duration between the operation and the complete wound healing. The wound healing is considered complete when the skin is closed and when the patient do not need to have dressings. A picture of the wound at the end of the wound healing process is taken for each patient. Secondary criteria of evaluation : At day 1, day7, day 14, day 21 and day 28 two data will be collected : * The pain during the dressings' change using a visual scale going from 0 (no pain) to 10 (very painful). * The bleeding (and exudate) of the wound which can be absent, low, moderate or abundant. The investigators will collect all the side effects described by the patients for each wound healing technique.

Interventions

BIOLOGICALAutologous platelets gel

Application of autologous platelets gel (Platelet Rich Fibrin) after the open palm surgical treatment of Dupuytren's disease.

DEVICEVaselitulle

application of standardized wound dressing after the open palm surgical treatment of Dupuytren's disease.

Sponsors

University Hospital, Marseille
CollaboratorOTHER
Centre Hospitalier Universitaire de Nice
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age \> 18 * Patient with Dupuytren's disease with an indication of surgical treatment using the open palm technique. * Agreement form signed * patient affiliated to the national health system.

Exclusion criteria

* Patients allergic to one of the components of the dressings used in this study. * Patients with insulin-requiring diabetes * Patients sustaining anti-cancer treatment. * Pregnant women. * Patients included in another study. * Patients who cannot come to the follow up visits.

Design outcomes

Primary

MeasureTime frame
Time duration between the operation and the complete wound healing.18 months

Secondary

MeasureTime frame
-The pain during the dressings' change using a visual scale going from 0 to 10. -The bleeding of the wound.18 months

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026